Fluorescent theranostics probes at the second near-IR region (NIR-II; 1.0–1.7 µm) are in
high demand for precise theranostics that minimize autofluorescence, reduce photon …

The scarcity of efficient imaging technologies for precise cancer treatment greatly drives the
development of new nanotheranostic based platforms that enable both diagnostic and …

Theranostics nanoplatforms offer opportunities for imaging-guided precision therapy and
hold great potential for clinical applications. In most reported works, the imaging unit has a …

Discrete Pt (II) metallacycles have potential applications in biomedicine. Herein, we
engineered a dual-modal imaging and chemo-photothermal therapeutic nano-agent 1 that …

Ruthenium complexes are emerging as potential complements to platinum drugs. They also
show promise as photo-diagnostic and therapeutic agents. However, most ruthenium …

To promote the clinical theranostic performances of platinum‐based anticancer drugs,
imaging capability is urgently desired, and their chemotherapeutic efficacy needs to be …

Despite the success of emissive Ruthenium (Ru) agents in biomedicine, problems such as
the visible‐light excitation/emission and single chemo‐or phototherapy modality still hamper …

Although Ru (II)-based agents are expected to be promising candidates for substituting Pt-
drug, their in vivo biomedical applications are still limited by the short excitation/emission …

This work reports a newly designed pH-activatable and aniline-substituted aza-boron-
dipyrromethene as a trifunctional photosensitizer to achieve highly selective tumor imaging …

The discovery of near‐IR‐II (NIR‐II) tumor phototheranostics holds a great promise for use in
nanomedicine on account of its enhanced penetration depth, high spatial resolution, and …